Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sunil Yadav

Showing results (51-60 of 60) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 60 results.
Cureus|November 5, 2025
ACE Inhibitors and ARBs in Chronic Kidney Disease: A Systematic Review of Randomized Controlled Trials on Albuminuria Reduction, eGFR Decline, and SafetyAnjali Avula, Loveleen K Johal, Fatima Ali, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|October 27, 2018
Slow-twitch skeletal muscle defects accompany cardiac dysfunction in transgenic mice with a mutation in the myosin regulatory light chainKatarzyna Kazmierczak, Jingsheng Liang, Chen-Ching Yuan, et al.
Bioorganic & Medicinal Chemistry|July 13, 2010
Synthesis and biological evaluation of arylidene analogues of Meldrum's acid as a new class of antimalarial and antioxidant agentsHarmeet S Sandhu, Sameer Sapra, Mukesh Gupta, et al.
Cureus|October 28, 2025
Mechanistic Insights Into the Cardioprotective Effects of Modern Glucose-Lowering Drugs in Type 2 Diabetes: A Systematic ReviewMounica Ratnala, Loveleen K Johal, Zulaihat F Galadima, et al.
Current Oncology (Toronto, Ont.)|February 26, 2026
Early Experience with Tarlatamab (T-Cell Engagers) for Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Canada: Lessons Learned and Implementation StrategiesParneet K Cheema, Kirstin A Perdrizet, Randeep S Sangha, et al.
Circulation|October 18, 2023
Improved Cardiac Performance and Decreased Arrhythmia in Hypertrophic Cardiomyopathy With Non-β-Blocking R-Enantiomer CarvedilolKinya Seo, Yuta Yamamoto, Anna Kirillova, et al.
Leukemia|July 13, 2024
Targeting CERS6-AS1/FGFR1 axis as synthetic vulnerability to constrain stromal cells supported proliferation in Mantle cell lymphomaUdita Jindal, Mukesh Mamgain, Uttam Kumar Nath, et al.
Leukemia|July 29, 2024
Correction: Targeting CERS6-AS1/FGFR1 axis as synthetic vulnerability to constrain stromal cells supported proliferation in Mantle cell lymphomaUdita Jindal, Mukesh Mamgain, Uttam Kumar Nath, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 23, 2014
Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinomaRobert J Motzer, Carlos H Barrios, Tae Min Kim, et al.
Cell Genomics|May 10, 2025
Identification of targetable vulnerabilities of PLK1-overexpressing cancers by synthetic dosage lethalityChelsea E Cunningham, Frederick S Vizeacoumar, Yue Zhang, et al.
Pageof 6

Showing results (51-60 of 60) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
Cureus|November 5, 2025
ACE Inhibitors and ARBs in Chronic Kidney Disease: A Systematic Review of Randomized Controlled Trials on Albuminuria Reduction, eGFR Decline, and SafetyAnjali Avula, Loveleen K Johal, Fatima Ali, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|October 27, 2018
Slow-twitch skeletal muscle defects accompany cardiac dysfunction in transgenic mice with a mutation in the myosin regulatory light chainKatarzyna Kazmierczak, Jingsheng Liang, Chen-Ching Yuan, et al.
Bioorganic & Medicinal Chemistry|July 13, 2010
Synthesis and biological evaluation of arylidene analogues of Meldrum's acid as a new class of antimalarial and antioxidant agentsHarmeet S Sandhu, Sameer Sapra, Mukesh Gupta, et al.
Cureus|October 28, 2025
Mechanistic Insights Into the Cardioprotective Effects of Modern Glucose-Lowering Drugs in Type 2 Diabetes: A Systematic ReviewMounica Ratnala, Loveleen K Johal, Zulaihat F Galadima, et al.
Current Oncology (Toronto, Ont.)|February 26, 2026
Early Experience with Tarlatamab (T-Cell Engagers) for Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Canada: Lessons Learned and Implementation StrategiesParneet K Cheema, Kirstin A Perdrizet, Randeep S Sangha, et al.
Circulation|October 18, 2023
Improved Cardiac Performance and Decreased Arrhythmia in Hypertrophic Cardiomyopathy With Non-β-Blocking R-Enantiomer CarvedilolKinya Seo, Yuta Yamamoto, Anna Kirillova, et al.
Leukemia|July 13, 2024
Targeting CERS6-AS1/FGFR1 axis as synthetic vulnerability to constrain stromal cells supported proliferation in Mantle cell lymphomaUdita Jindal, Mukesh Mamgain, Uttam Kumar Nath, et al.
Leukemia|July 29, 2024
Correction: Targeting CERS6-AS1/FGFR1 axis as synthetic vulnerability to constrain stromal cells supported proliferation in Mantle cell lymphomaUdita Jindal, Mukesh Mamgain, Uttam Kumar Nath, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 23, 2014
Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinomaRobert J Motzer, Carlos H Barrios, Tae Min Kim, et al.
Cell Genomics|May 10, 2025
Identification of targetable vulnerabilities of PLK1-overexpressing cancers by synthetic dosage lethalityChelsea E Cunningham, Frederick S Vizeacoumar, Yue Zhang, et al.
Pageof 6